Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Higher vs standard adalimumab dosing in moderately to severely active ulcerative colitis (M14-033)
jRCT2080222597Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in autoimmune colitis (5 arms), sponsored by AbbVie Inc. Started Sep 2014; status: completed.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080222597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222597.